The in-house versus outsourced clinical operations decision is usually framed as a cost question. That framing misses what actually determines whether it works: not which model is cheaper on a spreadsheet, but which model your organisation has the maturity to govern well.
The real cost comparison is rarely apples to apples
A fully loaded in-house clinical operations team looks expensive against a CRO's per-study proposal, but the comparison usually omits the internal governance cost of managing a CRO relationship well — oversight staff, vendor management systems, escalation processes. Conversely, in-house cost estimates often omit the ramp-up time and hiring risk of building a team fast enough to support an active pipeline. Compare total cost of governance, not just headcount versus contract value.
In-house works when you have consistent, predictable volume
Organisations running a steady pipeline of similar studies benefit from an in-house team's accumulated therapeutic and operational knowledge — institutional memory that a new CRO team has to rebuild on every engagement. The economics favour in-house when volume is consistent enough to keep a team productively utilised between studies, not sitting idle waiting for the next protocol.
Outsourcing works when you need to flex quickly
A biotech moving from a single asset to a broader pipeline, or a sponsor entering a new therapeutic area or geography, benefits from a CRO's ability to scale resource up or down without the fixed cost and hiring lead time of building internal capability. The tradeoff is a genuine loss of direct control, which needs to be replaced with strong oversight — not left unmanaged.
Hybrid models are common, and often mismanaged
Most mid-sized sponsors run a hybrid: an internal core team overseeing outsourced execution. This model works well when the internal team's role is clearly defined as oversight and decision-making, not as a thin layer duplicating what the CRO already does. It works poorly when responsibilities blur, and issues fall into the gap between "we assumed the CRO was handling it" and "we assumed the sponsor team was handling it."
The question that actually predicts success
Before choosing a model, ask honestly: does our organisation have the governance discipline to oversee outsourced work well, or the operational maturity to run in-house work well? Neither model compensates for weak governance. A poorly overseen CRO relationship and a poorly managed in-house team fail in similar ways — inconsistent quality, late-surfacing problems, and TMFs that do not withstand inspection.
Revisit the decision as your organisation changes
The right model at 2 studies a year is often wrong at 10, and the right model during a single pivotal study is often wrong once you have an approved product generating post-marketing commitments. Treat this as a decision to revisit at defined growth points, not a one-time structural choice made at company founding and never reconsidered.
Getting an independent view
Because this decision is rarely purely financial, an outside perspective — one without a stake in defending the current structure — often surfaces considerations that internal discussions miss. Our Clinical Trial Consulting service includes operational strategy support for sponsors evaluating whether to build, outsource, or restructure their clinical operations model.